Skip to main content
Premium Trial:

Request an Annual Quote

Agendia Closes Third Round of Financing; In Talks With FDA for US Launch

NEW YORK, June 2 (GenomeWeb News) - Dutch biotech Agendia has closed a third round of financing with the Van Herk Group and Gilde Healthcare, the company said today. It did not disclose the amount of the financing.

 

The cash will help Agendia develop its microarray-based late stage products into diagnostics for breast cancer and other cancer types. It will also help the company to globally market its CupPrint and MammaPrint prognostic breast cancer tests.

 

Agendia CEO Bernhard Sixt said the company is expanding its EU presence and is in "advanced" talks with the FDA to enter the US market.

 

Van Herk Group, Gilde Healthcare, AXA Private Equity Venture Funds, Global Life Sciences Ventures, and the Netherlands Cancer Institute are current investors.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.